Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 6 (2009), Issue 10 (October)

1. Detection of aggressive primary prostate cancer with 11C-choline PET/CT using multimodality fusion techniques.
   J Nucl Med, 50(10): 1585-93. [Abstract] [Full-text]
2. 2-18F-Fluoropropionic acid as a PET imaging agent for prostate cancer.
   J Nucl Med, 50(10): 1709-14. [Abstract] [Full-text]
3. Expression of RIZ1 protein (Retinoblastoma-interacting zinc-finger protein 1) in prostate cancer epithelial cells changes with cancer grade progression and is modulated in vitro by DHT and E2.
   J Cell Physiol, 221(3): 771-7. [Abstract] [Full-text]
4. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target.
   Lancet Oncol, 10(10): 981-91. [Abstract] [Full-text]
5. Health-related quality of life evaluation in patients undergoing cavernous nerve reconstruction during radical prostatectomy.
   Jpn J Clin Oncol, 39(10): 671-6. [Abstract] [Full-text]
6. The role of SPARC in the TRAMP model of prostate carcinogenesis and progression.
   Oncogene, 28(39): 3487-98. [Abstract] [Full-text]
7. Cutting Edge: Tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells.
   J Immunol, 183(8): 4848-52. [Abstract] [Full-text]
8. Study of robustness of IMPT and IMRT for prostate cancer against organ movement.
   Int J Radiat Oncol Biol Phys, 75(3): 941-9. [Abstract] [Full-text]
9. Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate.
   Cancer Cell, 16(4): 336-46. [Abstract] [Full-text]
10. Percutaneous fluoroscopically guided salvage of misplaced perirectal (125)I prostate seeds-easy way out.
    Urology, 74(4): 924-5. [Abstract] [Full-text]
11. Association between manganese superoxide dismutase gene polymorphism and risk of prostate cancer: a meta-analysis.
    Urology, 74(4): 884-8. [Abstract] [Full-text]
12. Second primary cancer risk of radiation therapy after radical prostatectomy for prostate cancer: an analysis of SEER data.
    Urology, 74(4): 866-71. [Abstract] [Full-text]
13. Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer.
    Urology, 74(4): 878-83. [Abstract] [Full-text]
14. Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network.
    Urology, 74(4): 873-7. [Abstract] [Full-text]
15. Identification of multipotent mesenchymal stromal cells in the reactive stroma of a prostate cancer xenograft by side population analysis.
    Exp Cell Res, 315(17): 3004-13. [Abstract] [Full-text]
16. Erectile function durability following permanent prostate brachytherapy.
    Int J Radiat Oncol Biol Phys, 75(3): 639-48. [Abstract] [Full-text]
17. Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: a sequential dose-escalation pilot study.
    Int J Radiat Oncol Biol Phys, 75(3): 656-63. [Abstract] [Full-text]
18. Urinary symptom flare in 712 125I prostate brachytherapy patients: long-term follow-up.
    Int J Radiat Oncol Biol Phys, 75(3): 649-55. [Abstract] [Full-text]
19. Annexin-A7 protects normal prostate cells and induces distinct patterns of RB-associated cytotoxicity in androgen-sensitive and -resistant prostate cancer cells.
    Int J Cancer, 125(11): 2528-39. [Abstract] [Full-text]
20. Housekeeping genes in prostate tumorigenesis.
    Int J Cancer, 125(11): 2603-8. [Abstract] [Full-text]
21. Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models.
    Int J Cancer, 125(11): 2711-20. [Abstract] [Full-text]
22. HER3 is required for the maintenance of neuregulin-dependent and -independent attributes of malignant progression in prostate cancer cells.
    Int J Cancer, 125(11): 2565-75. [Abstract] [Full-text]
23. Sphingosine kinase 1 inhibition sensitizes hormone-resistant prostate cancer to docetaxel.
    Int J Cancer, 125(11): 2728-36. [Abstract] [Full-text]
24. Exposure of treating physician to radiation during prostate brachytherapy using iodine-125 seeds: dose measurements on both hands with thermoluminescence dosimeters.
    Strahlenther Onkol, 185(10): 689-95. [Abstract] [Full-text]
25. aPKClambda/iota promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6.
    Proc Natl Acad Sci U S A, 106(38): 16369-74. [Abstract] [Full-text]
26. XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors.
    Proc Natl Acad Sci U S A, 106(38): 16351-6. [Abstract] [Full-text]
27. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration.
    Proc Natl Acad Sci U S A, 106(38): 16157-62. [Abstract] [Full-text]
28. Replication of prostate cancer risk loci in a Japanese case-control association study.
    J Natl Cancer Inst, 101(19): 1330-6. [Abstract] [Full-text]
29. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.
    J Natl Cancer Inst, 101(19): 1325-9. [Abstract] [Full-text]
30. Inhibition of epithelial to mesenchymal transition in metastatic prostate cancer cells by the novel proteasome inhibitor, NPI-0052: pivotal roles of Snail repression and RKIP induction.
    Oncogene, 28(40): 3573-85. [Abstract] [Full-text]
31. Transcription variants of the prostate-specific PrLZ gene and their interaction with 14-3-3 proteins.
    Biochem Biophys Res Commun, 389(3): 455-60. [Abstract] [Full-text]
32. Prostate specific antigen best practice statement: 2009 update.
    J Urol, 182(5): 2232-41. [Abstract] [Full-text]
33. The use of a surgical patch in the prevention of lymphoceles after extraperitoneal pelvic lymphadenectomy for prostate cancer: a randomized prospective pilot study.
    J Urol, 182(5): 2285-90. [Abstract] [Full-text]
34. Transperitoneal laparoscopic prostatectomy does not increase small bowel within the target volume for postoperative radiotherapy.
    J Urol, 182(5): 2280-4. [Abstract] [Full-text]
35. Prostate cancer early detection program recruitment methods and show rates in men at high risk.
    J Urol, 182(5): 2212-7. [Abstract] [Full-text]
36. Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy.
    J Urol, 182(5): 2265-72. [Abstract] [Full-text]
37. Pathological stage T2 subgroups to predict biochemical recurrence after prostatectomy.
    J Urol, 182(5): 2291-5. [Abstract] [Full-text]
38. Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails.
    J Urol, 182(5): 2274-8. [Abstract] [Full-text]
39. A framework for the identification of men at increased risk for prostate cancer.
    J Urol, 182(5): 2112-20. [Abstract] [Full-text]
40. Exercise and prostate cancer risk in a cohort of veterans undergoing prostate needle biopsy.
    J Urol, 182(5): 2226-31. [Abstract] [Full-text]
41. Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras.
    J Urol, 182(5): 2242-8. [Abstract] [Full-text]
42. Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database.
    J Urol, 182(5): 2250-5. [Abstract] [Full-text]
43. Increased low density lipoprotein and increased likelihood of positive prostate biopsy in black americans.
    J Urol, 182(5): 2219-25. [Abstract] [Full-text]
44. Differing perceptions of quality of life in patients with prostate cancer and their doctors.
    J Urol, 182(5): 2296-302. [Abstract] [Full-text]
45. Imaging metastatic bone disease from carcinoma of the prostate.
    Br J Cancer, 101(8): 1225-32. [Abstract] [Full-text]
46. Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer.
    Br J Cancer, 101(8): 1248-52. [Abstract] [Full-text]
47. DKC1 overexpression associated with prostate cancer progression.
    Br J Cancer, 101(8): 1410-6. [Abstract] [Full-text]
48. Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer.
    Br J Cancer, 101(8): 1233-40. [Abstract] [Full-text]
49. Does diabetes mellitus modify the association between 17q12 risk variant and prostate cancer aggressiveness?
    BJU Int, 104(9): 1200-3. [Abstract] [Full-text]
50. Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase.
    BJU Int, 104(9): 1191-7. [Abstract] [Full-text]
51. The promiscuous receptor.
    BJU Int, 104(9): 1204-7. [Abstract] [Full-text]
52. Tumour length of the largest focus predicts prostate-specific antigen-based recurrence after radical prostatectomy in clinically localized prostate cancer.
    BJU Int, 104(9): 1215-8. [Abstract] [Full-text]
53. Differences among patients undergoing perineal or retropubic radical prostatectomy in pain and perioperative variables: a prospective study.
    BJU Int, 104(9): 1219-26. [Abstract] [Full-text]
54. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
    BJU Int, 104(9): 1208-14. [Abstract] [Full-text]
55. Recovery of erectile function after radical prostatectomy is quantitatively related to the response to intraoperative cavernous nerve stimulation.
    BJU Int, 104(9): 1252-7. [Abstract] [Full-text]
56. Meat and meat-related compounds and risk of prostate cancer in a large prospective cohort study in the United States.
    Am J Epidemiol, 170(9): 1165-77. [Abstract] [Full-text]
57. New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy.
    Cancer Immunol Immunother, 59(1): 63-71. [Abstract] [Full-text]
58. Rare primary extranodal lymphomas: diffuse large B-cell lymphomas of the genital tract.
    Ann Hematol, 88(12): 1223-8. [Abstract] [Full-text]
59. Overexpression of the potential kinase serine/ threonine/tyrosine kinase 1 (STYK 1) in castration-resistant prostate cancer.
    Cancer Sci, 100(11): 2109-14. [Abstract] [Full-text]
60. Piceatannol, a natural stilbene from grapes, induces G1 cell cycle arrest in androgen-insensitive DU145 human prostate cancer cells via the inhibition of CDK activity.
    Cancer Lett, 285(2): 166-73. [Abstract] [Full-text]
61. Silibinin inhibits expression of HIF-1alpha through suppression of protein translation in prostate cancer cells.
    Biochem Biophys Res Commun, 390(1): 71-6. [Abstract] [Full-text]
62. Rethinking screening for breast cancer and prostate cancer.
    JAMA, 302(15): 1685-92. [Abstract] [Full-text]
63. Prospective study of Trichomonas vaginalis infection and prostate cancer incidence and mortality: Physicians' Health Study.
    J Natl Cancer Inst, 101(20): 1406-11. [Abstract] [Full-text]
64. Identification of novel androgen-responsive genes by sequencing of LongSAGE libraries.
    BMC Genomics, 10: 476. [Abstract] [Full-text]
65. The novel tumor-suppressor Mel-18 in prostate cancer: its functional polymorphism, expression and clinical significance.
    Int J Cancer, 125(12): 2836-43. [Abstract] [Full-text]
66. Castration induces autoantibody and T cell responses that correlate with inferior outcomes in an androgen-dependent murine tumor model.
    Int J Cancer, 125(12): 2871-8. [Abstract] [Full-text]
67. Systemic delivery of siRNA specific to tumor mediated by atelocollagen: combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer.
    Int J Cancer, 125(12): 2978-90. [Abstract] [Full-text]
68. Strategies for online organ motion correction for intensity-modulated radiotherapy of prostate cancer: prostate, rectum, and bladder dose effects.
    Int J Radiat Oncol Biol Phys, 75(4): 1254-60. [Abstract] [Full-text]
69. In vivo dosimetry with a linear MOSFET array to evaluate the urethra dose during permanent implant brachytherapy using iodine-125.
    Int J Radiat Oncol Biol Phys, 75(4): 1266-72. [Abstract] [Full-text]
70. Dosimetric study of pelvic proton radiotherapy for high-risk prostate cancer.
    Int J Radiat Oncol Biol Phys, 75(4): 994-1002. [Abstract] [Full-text]
71. Need for high radiation dose (>or=70 gy) in early postoperative irradiation after radical prostatectomy: a single-institution analysis of 334 high-risk, node-negative patients.
    Int J Radiat Oncol Biol Phys, 75(4): 966-74. [Abstract] [Full-text]
72. Measuring time to biochemical failure in the TROG 96.01 trial: when should the clock start ticking?
    Int J Radiat Oncol Biol Phys, 75(4): 1008-12. [Abstract] [Full-text]
73. Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse.
    Int J Radiat Oncol Biol Phys, 75(4): 983-9. [Abstract] [Full-text]
74. Retrospective comparison of external beam radiotherapy and radical prostatectomy in high-risk, clinically localized prostate cancer.
    Int J Radiat Oncol Biol Phys, 75(4): 975-82. [Abstract] [Full-text]
75. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
    Int J Radiat Oncol Biol Phys, 75(4): 1013-20. [Abstract] [Full-text]
76. Correlation between dosimetric parameters and late rectal and urinary toxicities in patients treated with high-dose-rate brachytherapy used as monotherapy for prostate cancer.
    Int J Radiat Oncol Biol Phys, 75(4): 1003-7. [Abstract] [Full-text]
77. Assessing the effect of a contouring protocol on postprostatectomy radiotherapy clinical target volumes and interphysician variation.
    Int J Radiat Oncol Biol Phys, 75(4): 990-3. [Abstract] [Full-text]
78. Inhibition of constitutive and cxc-chemokine-induced NF-kappaB activity potentiates ansamycin-based HSP90-inhibitor cytotoxicity in castrate-resistant prostate cancer cells.
    Br J Cancer, 101(9): 1620-9. [Abstract] [Full-text]
79. PTPIP51 mRNA and protein expression in tissue microarrays and promoter methylation of benign prostate hyperplasia and prostate carcinoma.
    Prostate, 69(16): 1751-62. [Abstract] [Full-text]
80. The relationship of neuroendocrine carcinomas to anti-tumor therapies in TRAMP mice.
    Prostate, 69(16): 1763-73. [Abstract] [Full-text]
81. Adiponectin increases motility of human prostate cancer cells via adipoR, p38, AMPK, and NF-kappaB pathways.
    Prostate, 69(16): 1781-9. [Abstract] [Full-text]
82. Tissue culture media supplemented with 10% fetal calf serum contains a castrate level of testosterone.
    Prostate, 69(16): 1724-9. [Abstract] [Full-text]
83. PSA surge/flare-up in patients with castration-refractory prostate cancer during the initial phase of chemotherapy.
    Prostate, 69(16): 1802-7. [Abstract] [Full-text]
84. The protective effect of diabetes mellitus against prostate cancer: role of sex hormones.
    Prostate, 69(16): 1744-50. [Abstract] [Full-text]
85. Effects of the 5 alpha-reductase inhibitor dutasteride on gene expression in prostate cancer xenografts.
    Prostate, 69(16): 1730-43. [Abstract] [Full-text]
86. Influence of zinc deficiency on Akt-Mdm2-p53 and Akt-p21 signaling axes in normal and malignant human prostate cells.
    Am J Physiol Cell Physiol, 297(5): C1188-99. [Abstract] [Full-text]

© 2004-2012 Prostate Cancer Research Today. All Rights Reserved.